TY - JOUR T1 - Familial hypercholesterolemia: Experience in the Lipid Clinic of Alava JO - Clínica e Investigación en Arteriosclerosis (English Edition) T2 - AU - Pérez García,Leire SN - 25299123 M3 - 10.1016/j.artere.2018.04.003 DO - 10.1016/j.artere.2018.04.003 UR - https://www.elsevier.es/en-revista-clinica-e-investigacion-arteriosclerosis-english-415-articulo-familial-hypercholesterolemia-experience-in-lipid-S2529912318000499 AB - IntroductionFamilial hypercholesterolaemia (FH) is the autosomal dominant genetic disorder most frequently associated with premature cardiovascular disease (CVD). Materials and methodsA retrospective, observational study was conducted to determine the clinical characteristics, analytical parameters and cardiovascular risk factors of 133 patients with a genetically confirmed diagnosis of FH on follow-up in the Lipid Clinic of Alava. ResultsCVD was observed in 8.30% of the patients (ischaemic heart disease in 100% of the cases). The LDL concentration goal was achieved in 40.6% (45.50% in primary prevention and 27.30% in secondary prevention). The large majority (81.80%) of patients with coronary heart disease (CHD) were male. The odds ratio (OR) of males having CHD compared to females is 4.97 (1.03–23.93, p=0.03). The OR of developing CHD in patients with a family history of premature CVD is 6.86 (1.32–35.67, p=p.02). A statistically significant association was found between smoking and the risk of CVD (p=0.005), and also between having diabetes and the risk of CVD (p=0.0001). If the treatment with statins begins at older than 40 years, the OR of suffering CHD is 6.40 (1.53–26.5) (p=0.009). The mean time from diagnosis to the cardiovascular event in the group of ex-smokers is 10.80±5.80 years, and in the non-smoking group it is 17.50±2.50 years (p=0.011). ConclusionsIn our reference population with FH, it was found that there was an increased risk of suffering a cardiovascular event in male patients, with a family history of premature CVD, diabetics, and in those in whom lipid lowering treatment was started after 40 years of age. ER -